Metabolic Comorbidity in Severe Mental Illness: Treating the Brain While Minding the Body-View Presentation

Video Transcription

Video Summary

Dr. Rob Cotez introduces a webinar on metabolic comorbidity in severe mental illness (SMI), emphasizing the dual focus on treating the brain and minding the body. The webinar features Dr. Margaret Han from the University of Toronto, whose research on metabolic risk in schizophrenia highlights the early onset of metabolic syndrome in this population, impacting life expectancy significantly.<br /><br />Dr. Han discusses how patients with schizophrenia often exhibit metabolic disorders like type 2 diabetes early in life, contributing to reduced life expectancy. She explores various contributing factors, including lifestyle elements, genetic factors, and the impact of antipsychotic treatments, which often exacerbate metabolic concerns. The webinar highlights challenges in accessing adequate medical care, emphasizing that SMI patients often face lower rates of metabolic monitoring.<br /><br />Treatment strategies for managing antipsychotic-induced weight gain are explored. Dr. Han outlines options: reducing the antipsychotic dose, switching medications, or implementing pharmacological and lifestyle interventions. Metformin shows promise for mitigating weight gain, particularly in first-episode populations. Additionally, newer treatments like GLP-1 receptor agonists (e.g., liraglutide and semaglutide) offer effective weight loss, although insurance coverage remains a challenge.<br /><br />Dr. Han underscores the importance of regular metabolic screening and intervention, advocating for a proactive management approach to mitigate the cardiovascular risks associated with antipsychotic treatment. The discussion includes practical tips for dietary adjustments and the importance of early, aggressive intervention to manage the metabolic side effects of psychotropic medications effectively.<br /><br />Overall, the webinar highlights the urgent need for more comprehensive research and tailored treatment strategies for addressing metabolic comorbidities in individuals with severe mental illness, emphasizing early intervention as a critical factor in improving outcomes.

Keywords

metabolic comorbidity

severe mental illness

schizophrenia

metabolic syndrome

antipsychotic treatment

metformin

GLP-1 receptor agonists

cardiovascular risks

lifestyle interventions

early intervention